Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
1,37 USD | -1,44 % | +0,74 % | -15,95 % |
21/03 | Transcript : InflaRx N.V. - Special Call | |
21/03 | InflaRx N.V. informa de los resultados de ganancias para el año completo finalizado el 31 de diciembre de 2023 | CI |
Resumen de negocios
Número de empleados: 62
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Monoclonal Antibodies
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Renfeng Guo
FOU | Founder | 53 | 01/12/07 |
Niels Riedemann
FOU | Founder | 51 | 01/12/07 |
Thomas Taapken
DFI | Director of Finance/CFO | 59 | 01/10/20 |
Camilla Chong
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/07/23 |
Daniel Vetter
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/22 |
Maria Habel
CTO | Chief Tech/Sci/R&D Officer | 41 | 01/01/08 |
Bruce P. Burnett
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/20 |
Jan Medina
IRC | Investor Relations Contact | - | 22/02 |
Nicole Bertsch
HRO | Human Resources Officer | - | 01/03/21 |
Christian Schmid
LAW | General Counsel | - | 01/01/21 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Nicolas Fulpius
FOU | Founder | 51 | 01/12/07 |
Niels Riedemann
FOU | Founder | 51 | 01/12/07 |
Renfeng Guo
FOU | Founder | 53 | 01/12/07 |
Hege Hellstrom
BRD | Director/Board Member | 59 | 01/04/23 |
Richard Brudnick
BRD | Director/Board Member | 67 | 14/02/19 |
Anthony Gibney
BRD | Director/Board Member | 53 | 06/02/18 |
Mark Kubler
BRD | Director/Board Member | 49 | 01/01/15 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 58 883 272 | 54 560 784 ( 92,66 %) | 0 | 92,66 % |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. |
Biotechnology
|
Sector
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
-15,95 % | 81,85 M | |
-3,46 % | 102 mil M | |
+1,41 % | 96,29 mil M | |
+2,13 % | 22,18 mil M | |
-15,84 % | 21,2 mil M | |
-9,21 % | 18,31 mil M | |
-39,98 % | 17,38 mil M | |
-14,65 % | 16,36 mil M | |
+4,39 % | 13,97 mil M | |
+31,35 % | 12,17 mil M |
- Bolsa de valores
- Acciones
- Acción IFRX
- Empresa InflaRx N.V.